{"name":"Fujifilm Kyowa Kirin Biologics Co., Ltd.","slug":"fujifilm-kyowa-kirin-biologics-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"FKB327","genericName":"FKB327","slug":"fkb327","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"FKB327","genericName":"FKB327","slug":"fkb327","phase":"phase_3","mechanism":"FKB327 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNNC1lbGZmZUw1QXpCOUotam52cDloS3RwbnhUWnBlN2JrTUVUMUw5enJEZjVLYmNaeEdid2tYQUgtSEZNSWZpc0Y4QVViSnY4WmNWZ0lKRC1kUzZiRUdGSXJyc3BWTEo1UzRyZERSOXF5YmVNOW81aWZHc1ZxaGd0Sw?oc=5","date":"2026-01-04","type":"patent","source":"Insightace Analytic","summary":"Psoriasis Biosimilars Market Size, Share and New Trends 2026 to 2035 - Insightace Analytic","headline":"Psoriasis Biosimilars Market Size, Share and New Trends 2026 to 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxObnBLZTdKWUZSX19mTGNsRzhER0d3VEtacHlNZHVaUk9GUGNPQWxVQ3F2Y1pIa1k4VzQ5c1BvQ0hqU01udE94RGlyYm9pdjFBRWtBekwxU21CWkVNTDg0akVKZzNhTEtueEZ1S1Jqa05HbkZ3Z2xkeHBzU1RBeDlXVUF5VlliVGEzeHRTWDJwS3RsUGdfaHFJcUI5cmlNc2RQZGZmQWhFQTdMcE3SAbABQVVfeXFMTTJwblRGTUd5Z3p5Y093Y3l6RDFoNzZEcm10Z2hySUllRmxPOFNTTFdVZlBYVTJtX2VLMUpiWkZXSWZrTVBxblZTSW9IRTQ1RWJoZU5vSEgxMHJNQzktUjFXbndKUmxlUmxXUk5pRzAycTFZZ0l0bThseHFOS0RsbFJHNElCR2FmX05GQTIyRjRfaGRaUmZIbHhsdUIyM3ZjelhTQlR5enAtdjB3OERUTVg?oc=5","date":"2025-12-23","type":"pipeline","source":"Express Pharma","summary":"Biocon Biologics secures global manufacturing and commercial rights for Hulio - Express Pharma","headline":"Biocon Biologics secures global manufacturing and commercial rights for Hulio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQVzZLY2tjdzROUXFXT1pSd3FEdm1sV2lhcTFDdHl5MkV1NU1BVW92aTBlbHB6MTR3V2gwX3ljLWtkYXlHeFJDcC1zb3dDT0lGWFNfcE4zbng3WVdzZW9VZ1FpSk96dmxQSGpUOERBUVVQVlo4bS1RcW15dEF1YndqTWROTGtPbkxVOEFTbExRUGJUaTRJeU9PLUZMZVFxUTRoNTZYUnBid0g2aVFBU2FBSWtLWXlsOE0wb1M2QjdGQ0tvOFNBbkwyOGFoeXdfeHg2cjJIMkh1dUZxUQ?oc=5","date":"2025-12-23","type":"regulatory","source":"scanx.trade","summary":"Biocon Partners With Ajanta Pharma to Market Semaglutide Across 26 International Markets - scanx.trade","headline":"Biocon Partners With Ajanta Pharma to Market Semaglutide Across 26 International Markets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQYjNrb1ZmNkxHdmlkS1RNZjJ6Q0VtT1d1d1ZMUXN6alNnOUVjM0s1bHFWWURZSFJHckxjWXJ0eU85UG9YVHBXTVBFUkFCQjFHSUFTam5VRWxwLVp2WFlJRzFmdTFnSFZJU0NTbk5idmttXy1faVJRU3lVOUNqWGVXWTJ3?oc=5","date":"2025-06-25","type":"patent","source":"Insightace Analytic","summary":"TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034. - Insightace Analytic","headline":"TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034.","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-09-07","type":"deal","source":"Medical Dialogues","summary":"Biocon Biologics completes integration of acquired biosimilars business from Viatris in North America - Medical Dialogues","headline":"Biocon Biologics completes integration of acquired biosimilars business from Viatris in North America","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-07-04","type":"patent","source":"Medical Dialogues","summary":"Biocon Biologics's Hulio biosimilar to Humira, now available in US - Medical Dialogues","headline":"Biocon Biologics's Hulio biosimilar to Humira, now available in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNZzZPeEIxYzBsTWtUc2dnY2g2X1pBc0psYU5La3FzZFVuV1RmSEtpbE4yU3Y0U19WRUh3WVhEVUtPR2ZQMmVXM2lkQ0Z2ZWRSY2dHbmN6Y0QtNzlXRjZDelEwamNsbXphQmxUdVZHN0xQRTBSUEVjRXdiTzkyLTlfTFFVNDFSWjdSbHp2Z3A0MDRjUWZnWG9BYV9reEFFUVRnTHNzajNZMllLbTNBMVE?oc=5","date":"2021-02-18","type":"patent","source":"Newswire Canada","summary":"Viatris Launches Hulio® (adalimumab biosimilar) in Canada - Newswire Canada","headline":"Viatris Launches Hulio® (adalimumab biosimilar) in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxNaFJ1WURfdWM0TWpXY2gyX0wtWmJnZXJlTTFOV1MxajF2N19MR3hnSFJUVmQ0WVBpOWdyTlNSNUcwOTd2T2VKMUtxWllBVXhFeS0zakNGd1ZjSnViRkN4bmkzWm1IR1VQd2tuZ2EtOEhnd25RWTN0Rm5wMWg1V3RmdVV3WFUxOEIwbVVrRXlKcGdYam16OXkxem84bGk1X3Q1c3lucFhMX2FQSXVGdmg2WlpyZ1U0T0xBNjBzREthTThSVzZjU3VOSzQxRXlsWnRtWnFSamhBWWprNzNHLXdvc0NIYl8zLWE4eXE0QURkQldwVURsQU1IeE5QNkJrQnQyMy11ZE1tcHhCQzBidnpiTg?oc=5","date":"2019-11-04","type":"pipeline","source":"Healthcare Packaging","summary":"PDA’s First Drug Delivery Innovation Award Winners at 2019 Universe of Pre-Filled Syringes and Injection Devices Conference - Healthcare Packaging","headline":"PDA’s First Drug Delivery Innovation Award Winners at 2019 Universe of Pre-Filled Syringes and Injection Devices Confere","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE9ValYtY3BNcVJLcGs3dUgzUFBBZHpNQ0pfblA3ak1VVXBBemhBenZnTTN0UENlN2pTVGpvR1FTLTJXX1o5TlNXR0lGN1UzLTVUT3BUTWVxTFltWThNMEZ1a1ZFTGU?oc=5","date":"2019-06-11","type":"patent","source":"Market.us","summary":"Adalimumab Biosimilar Market Size, Trends | CAGR Of 23.4% - Market.us","headline":"Adalimumab Biosimilar Market Size, Trends | CAGR Of 23.4%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNOGFqSVNJYi0yS2w0dFpxQjhJZFRyUldoVS1KWmpLMW5peW5PVmpuMDJHSWVfamMxQTN0SHh5a3hWRUF5b3c2YlFQRGF4MFB3ZUZSSmZMSkRuQmhBR3cxak9TaTNTM0oxUnEtUVZ1T1RtcG5USmxRcUg5MjBBYWpaU3VSeUNJaFE?oc=5","date":"2018-04-12","type":"patent","source":"BioPharma Dive","summary":"Mylan bets future on complex generics - BioPharma Dive","headline":"Mylan bets future on complex generics","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}